| Description | PDE4-IN-13 is a phosphodiesterase 4 (PDE4) inhibitor exhibiting anti-inflammatory and antioxidant activities, with an half maximal inhibitory concentration (IC50) value of 1.56 μM. It is used in the research of chronic obstructive pulmonary disease (COPD) [1]. |
| In vitro | PDE4-IN-13（化合物6o）能显著抑制RAW264.7巨噬细胞内由LPS诱导的TNF-α产出，并降低小鼠肺组织匀浆中Fe 2+诱发的MDA生成。此外，PDE4-IN-13在还原Fe 3+以及络合Fe 2+方面也表现出卓越的效果[1]。 |
| In vivo | PDE4-IN-13（化合物 6o）以50 mg/kg和100 mg/kg剂量腹膜内注射，能显著抑制LPS引发的小鼠血清中TNF-α的升高[1]。 |
| Target activity | PDE4:1.56 μM |
| molecular weight | 340.37 |
| Molecular formula | C20H20O5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |